When is crossover desirable in cancer drug trials and when is it problematic?

A. Haslam, V. Prasad

Research output: Contribution to journal › Editorial › peer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'When is crossover desirable in cancer drug trials and when is it problematic?'. Together they form a unique fingerprint.